Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Sayegh

Showing results (31-40 of 71) with videos related to

Pageof 8
Sort By:
The Prostate|August 30, 2023
Impact of androgen receptor alterations on cell-free DNA genomic profiling on survival outcomes in metastatic castration-resistant prostate cancerNishita Tripathi, Vinay Mathew Thomas, Nicolas Sayegh, et al.
Clinical Genitourinary Cancer|January 9, 2023
Association of Androgen Deprivation Therapy with Metabolic Disease in Prostate Cancer Patients: An Updated Meta-AnalysisJustin Swaby, Ankita Aggarwal, Akshee Batra, et al.
Human Pathology|January 26, 2024
Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathwayJon Mahlow, Marc Barry, Daniel J Albertson, et al.
JAMA Network Open|August 1, 2023
Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 TrialNicolas Sayegh, Umang Swami, Yeonjung Jo, et al.
Clinical Genitourinary Cancer|December 25, 2024
Real-world Effectiveness of Single-Agent Enfortumab Vedotin in Patients With Advanced Urothelial CarcinomaNicolas Sayegh, Yeonjung Jo, Georges Gebrael, et al.
Prostate Cancer and Prostatic Diseases|August 24, 2023
Correction: Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitorsGeorges Gebrael, Nicolas Sayegh, Vinay Mathew Thomas, et al.
Prostate Cancer and Prostatic Diseases|July 17, 2023
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitorsGeorges Gebrael, Nicolas Sayegh, Vinay Mathew Thomas, et al.
Cancers|October 13, 2021
Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United StatesUmang Swami, Jennifer Anne Sinnott, Benjamin Haaland, et al.
Bladder Cancer (Amsterdam, Netherlands)|April 1, 2026
Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumabGeorges Gebrael, Yeonjung Jo, Zeynep Irem Ozay, et al.
The Oncologist|August 23, 2021
Radium-223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy ResultsBenjamin L Maughan, Adam Kessel, Taylor Ryan McFarland, et al.
Pageof 8

Showing results (31-40 of 71) with videos related to

Sort By:
Pageof 8
The Prostate|August 30, 2023
Impact of androgen receptor alterations on cell-free DNA genomic profiling on survival outcomes in metastatic castration-resistant prostate cancerNishita Tripathi, Vinay Mathew Thomas, Nicolas Sayegh, et al.
Clinical Genitourinary Cancer|January 9, 2023
Association of Androgen Deprivation Therapy with Metabolic Disease in Prostate Cancer Patients: An Updated Meta-AnalysisJustin Swaby, Ankita Aggarwal, Akshee Batra, et al.
Human Pathology|January 26, 2024
Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathwayJon Mahlow, Marc Barry, Daniel J Albertson, et al.
JAMA Network Open|August 1, 2023
Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 TrialNicolas Sayegh, Umang Swami, Yeonjung Jo, et al.
Clinical Genitourinary Cancer|December 25, 2024
Real-world Effectiveness of Single-Agent Enfortumab Vedotin in Patients With Advanced Urothelial CarcinomaNicolas Sayegh, Yeonjung Jo, Georges Gebrael, et al.
Prostate Cancer and Prostatic Diseases|August 24, 2023
Correction: Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitorsGeorges Gebrael, Nicolas Sayegh, Vinay Mathew Thomas, et al.
Prostate Cancer and Prostatic Diseases|July 17, 2023
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitorsGeorges Gebrael, Nicolas Sayegh, Vinay Mathew Thomas, et al.
Cancers|October 13, 2021
Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United StatesUmang Swami, Jennifer Anne Sinnott, Benjamin Haaland, et al.
Bladder Cancer (Amsterdam, Netherlands)|April 1, 2026
Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumabGeorges Gebrael, Yeonjung Jo, Zeynep Irem Ozay, et al.
The Oncologist|August 23, 2021
Radium-223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy ResultsBenjamin L Maughan, Adam Kessel, Taylor Ryan McFarland, et al.
Pageof 8